anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Garcinia mangostana L. (mangosteen) is a tropical tree native to Southeast Asia. The pericarp of mangosteen fruit is used in traditional medicine to treat inflammation, infections, wounds, and diarrhea. The proposed health-promoting effects have been attributed to a family of polyphenols referred to as xanthones. Since its introduction into the United States, juices and products containing mangosteen fruit have become a top-selling botanical dietary supplement. This commercial success largely has been the result of aggressive marketing of health claims based on in vitro observations and anecdotal reports.

The purpose of this study was to determine the bioavailability of xanthones from mangosteen juice in adult human subjects. After an overnight fast of at least 10h, male and female subjects were admitted to the Ohio State University Clinical Research Center. Volunteers ingested 2 ounces of 100% mangosteen juice as part of a western-style breakfast. Pericarp particles accounted for 1% of the mass and 99% of total xanthone content in the juice. This dose provided 130 ± 2 mg total xanthones. Blood was collected prior to breakfast and 1,2,3,4,6,8 and 24h. Subjects were fed a mangosteen-free lunch and released from the unit after the 8h collection, refraining from mangosteen containing products until final collection of blood at 24h. Urine was collected for the 24 test period.
Patients receive standard of care preparative chemotherapy and undergo auto-HCT. Beginning 100-140 days after transplant, patients receive rituximab IV or rituximab and hyaluronidase human SC or any approved rituximab biosimilar at the approved dose once every 8 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET, CT or PET/CT throughout the study. Patients may undergo blood sample collection during screening and on study. Patients also may undergo bone marrow biopsy and aspirate during screening.
Cardiac fibrosis is characterized by the over-proliferation, over-transdifferentiation and over-deposition of extracellular matrix (ECM) of cardiac fibroblasts (CFs). Cardiac sympathetic activation is one of the leading causes of myocardial fibrosis. Meanwhile, cardiac fibrosis is often together with cardiac inflammation, which accelerates fibrosis by mediating inflammatory cytokines secretion. Recently, the Janus kinase/signal transducer and activator of transcription (JAK/STAT3) signaling pathway has been confirmed by its vital role during the progression of cardiac fibrosis. Thus, JAK/STAT3 signaling pathway is thought to be a potential therapeutic target for cardiac fibrosis. Baricitinib (BR), a novel JAK1/2 inhibitor, has been reported excellent effects of anti-fibrosis in multiple fibrotic diseases. However, little is known about whether and how BR ameliorates cardiac fibrosis caused by chronic sympathetic activation. Isoproterenol (ISO), a β-Adrenergic receptor (β-AR) nonselective agonist, was used to modulate chronic sympathetic activation in mice. As expected, our results proved that BR ameliorated ISO-induced cardiac dysfunction. Meanwhile, BR attenuated ISO-induced cardiac fibrosis and cardiac inflammation in mice. Moreover, BR also inhibited ISO-induced cardiac fibroblasts activation and macrophages pro-inflammatory secretion. As for mechanism studies, BR reduced ISO-induced cardiac fibroblasts by JAK2/STAT3 and PI3K/Akt signaling, while reduced ISO-induced macrophages pro-inflammatory secretion by JAK1/STAT3 and NF-κB signaling. In summary, BR alleviates cardiac fibrosis and inflammation caused by chronic sympathetic activation. The underlying mechanism involves BR-mediated suppression of JAK1/2/STAT3, PI3K/Akt and NF-κB signaling.
The rising prevalence of obesity among children and adolescents is a global public health concern, significantly contributing to noncommunicable chronic diseases such as cardiovascular disease, diabetes and cancer. In Croatia, obesity rates are alarmingly high, affecting both children and adults. Data from the Institute of the Public Health of Split-Dalmatian County were analyzed to identify trends in body mass index (BMI) among primary school students in Split, Croatia and possible connection with sports participation and parental education levels. A longitudinal analysis of students was conducted across three medical examinations during primary school education. The findings showed an increase in the prevalence of overweight and obesity from 23.4% in the first to 30.2% in the fifth grade, returning back to 23.4% in the eighth grade. Significant differences among students were associated with parental education level. Boys who participated in sports demonstrated a higher BMI in the first grade but there was no difference in BMI in later grades. Sports participation had no significant impact on the BMI of girls. The study underscores the critical role of parental education in influencing children's weight status and highlights the necessity of tailored public health interventions to address these trends from an early age. The implementation of comprehensive strategies, including educational programs and policy measures as part of the national health policy, is the only way to combat childhood obesity and promote long-term health benefits.
Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
Patients were randomly divided into intervention and control groups, with both groups receiving standard treatment and care for sepsis (decided by the attending physician). On this basis, the following treatments were administered: Intervention group (n=20): intravenous drip of ceftriaxone sodium 1g per dose, twice daily (continuously for 14 days), mecobalamin injection 1mg per dose, once daily (on days 1, 2, 3, 5, 7, 9, 11, 13), with a half-hour interval between medications. From day 15 to 28, take mecobalamin tablets orally, 1mg per dose, three times a day.
The invention provides a production process for a freeze-dried mask, which comprises the following steps: s1: preparing a freeze-drying precursor solution; s2: uniformly spreading the freeze-dried precursor solution on the first layer of spunlace fabric; s3: repeating the steps S1-S2 for N times, wherein N is more than or equal to 0; respectively obtaining coating freeze-drying spunlaced fabrics with different compositions; s4: compounding the single-layer or multi-layer coated spunlaced cloth to form a composite modified coated spunlaced cloth, and blanking the cloth into a specified shape; s5: filling the semi-finished facial mask into a sealed packaging bag; s6: preparing an auxiliary agent solution; s7: and (4) filling the auxiliary agent into a sealed packaging tank. Has good whitening effect and longer facial mask effect. The effect stability is better, and the security is good. Mannitol has effects of shrinking water and keeping moisture, and asiaticoside is beneficial for removing pockmark. The snail mucus extract can promote skin regeneration. Thereby the facial mask is more suitable for the use requirements of more people.
Obesity is a common clinical problem in most developed nations and is also rapidly becoming a major health concern in developing nations. Overweight individuals frequently suffer from several metabolic disorders such as insul in resistance, type 2 diabetes and dyslipidemia. This invention discloses proof  of principle for the role PPA.delta. (also known as .beta.) plays in the development of diet-induced obesity. In accordance with the present inventio n, a new method for treating obesity, insulin resistance and hyperlipidemia through administration of a pharmaceutical composition containing a chemical  agent that antagonizes the function of PPAR.delta.(.beta. protein, decreases  PPAR.delta.(.beta. gene expression and or transactivation of PPAR.delta.(.beta. target gene expression is disclosed. This invention also proposes that obese, insulin resistant hyperlipidemic patients can be effectively treated with a combination of a PPAR.delta.(.beta. antagonist wi th either an antidiabetic agent or a lipid-lowering agent (or both).
The present invention is a kit for use by a person to apply a daily treatment of medication and therapy to remove a corn or callus from the person's skin while providing maximum comfort to the person and minimal damage to healthy skin. In one embodiment, the kit comprises a box, an AM treatment system, and a PM treatment system for application at night. The AM treatment system comprises a plurality of AM foam bandages each having a medicated foam pad of hydrocolloid. The PM treatment system comprises a plurality of PM foam protective covers and a plurality of PM medicated non-woven patches impregnated with salicylic acid. The PM treatment system allows the person to remove a single PM medicated patch, trim it to fit the shape of the corn, and position it as desired over the corn. The person may then remove a single PM foam protective cover and apply it over the PM medicated patch, covering it completely, thereby limiting migration of the salicylic acid to healthy skin. Upon removal of the PM foam protective cover, the PM medicated patch along with a portion of the dead skin is removed neat and clean. The treatment cycle begins anew, wherein the AM foam bandage has the opportunity to heal any healthy skin that may have inadvertently come into contact with the salicylic acid of the PM treatment system as well as softening additional dead skin of the corn prior to the application of the next PM treatment system.
This is a research study comparing the outcomes of LASIK surgery to PRK surgery for nearsightedness when using the two different procedures. You will have one eye treated with LASIK using the Intralase FS laser and your other eye treated with PRK. You will be one of 100 sighted patients at Stanford to undergo treatment in this clinical research trial. This will be a prospective, randomized, research study in which up to 200 consecutive eyes scheduled to undergo excimer laser in situ keratomileusis (LASIK) in one eye and photorefractive keratectomy (PRK) in the fellow eye for the correction of myopia (nearsightedness) with or without astigmatism will be enrolled. The choice of which eye receives LASIK and which eye receives PRK will be randomized prior to enrollment. Randomization will be done according to a randomization schedule. You will know which eye is being treated with which procedure. The randomization will determine only whether your right or left eye is treated with the LASIK procedure. The other eye will be treated with PRK. You have a fifty percent chance of having your left eye treated with LASIK as your right eye. Subjects will undergo either bilateral (both eyes at once) wavefront (a more precise custom laser system) guided LASIK and PRK treatments using the VISX Star S4 excimer laser. All subjects will be followed for one year after the vision correction procedure. Subjects scheduled to undergo LASIK and PRK for the correction of myopia (nearsightedness) with or without astigmatism will be screened for eligibility. Eligible subjects will be examined preoperatively to establish a baseline for ocular condition (the general health and glasses prescription of the eyes). Postoperatively, subjects will undergo an ophthalmic evaluation (complete eye examination) at regular intervals as specified in this protocol. Retreatments (a second operation on the same eye for residual nearsightedness) will not be allowed during the first six months of this study. If you elect to undergo a retreatment of your LASIK or PRK surgery prior to the 6-month post-operative visit, the retreated eye will be exited from the study as of the retreatment date.

Any significant new finding developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject or subject's representative in a timely manner.
The present invention is directed to a material (10) which can be used to deliver a drug, such as an antibiotic, into a diseased tissue pocket (12), such as a periodontal pocket. The material (10) is preferably a bioerodible polymer such as a poly(orthoester), a polylactic acid, a polyglycolic acid or a copolymer or mixture thereof. The polymer containing the drug is heated to a physiologically compatible elevated temperature prior to injection into the tissue pocket (12). Once the bioerodible material (10) is injected into the pocket (12), the material (10) cools to the body temperature of the pocket (12). As it cools, the material (10) hardens and remains in place in the tissue pocket (12). The hardened material (10) bioerodes in the pocket (12) and releases the drug over a period of several days.
Fifteen healthy smokers are given single doses of General Onyx 1 g portion snus and General White 1g portion snus, respectively, and one piece of Nicorette 4 mg chewing gum. Serial blood samples are drawn before (0), 2, 4, 8, 16, 24, 30, 45, 60 minutes, 1.5, 2, 4, 6 and 8 hours after administration for determination of nicotine. Mean + SD extracted dose of nicotine from each preparation will be estimated. The percentage extracted of the nicotine content will be calculated. Cmax and Tmax will be estimated. A comparison to Nicorette 4 mg chewing gum will be made. The dose absorbed into the systemic blood circulation (AUC) in relation to the dose following the 4 mg Nicorette chewing gum will be calculated. Self-reports of subjective effects will be obtained up to 30 minutes after the test product is administered using a 100 mm visual analogue scale (VAS) anchored with "not at all" to "extremely".

The subjects are male and female smokers, smoking a minimum of 7 cigarettes per day. They should have no history of cardiac, kidney or hepatic disease, alcohol abuse or drug dependence. A physical examination including ECG and blood pressure should give no evidence of disease. No abnormalities should be found in a routine laboratory screening.

The subjects are requested not to smoke or to use any other form of nicotine containing products from 8 p.m. the day before each session until the last blood sample in each session. Previous experience has shown that subjects that have abstained from smoking for 12 hours have a plasma nicotine value of \<4 ng/ml. A value \>4 ng/ml prior to start of administration should lead to exclusion from statistical analysis. The subjects must be fasting overnight from 12 p.m. the day before each session. No food and drink are allowed from 15 minutes prior to and until 60 minutes after drug administration.
A cosmetic composition and an emulsion composition comprising 0.1-99 wt. % of an oleaginous component and 99.9-1 wt. % of an aqueous component, wherein cis-$g(D)9-octadecenoic acid or its derivative accounts for at least 85 wt. % of the oleaginous component, and cis-$g(D)9-unsaturated fatty acid or its derivative accounts for at least 90 wt. % while fatty acids other than the cis-$g(D)9-unsaturated fatty acids, their derivatives or other oleaginous components account for at most 10 wt. %. Since the oleaginous component contains cis-$g(D)9-octadecenoic acid or its derivative in a high concentration, it is possible to provide a cosmetic composition having heretofore unattainable excellent comfort in use and long-term stability and an emulsion composition having excellent emulsification stability.
RelA/p65 is as a crucial component of the nuclear factor κB (NF-κB) signaling pathway that has a significant impact on various fibrotic diseases. However, its role in the fibrosis of tissues surrounding the joint after traumatic injury remains unclear. In this study, rats were divided into three groups: non-operated control (NC) group, p65-siRNA treated (siRNA-p65) group, and negative siRNA treated (siRNA-neg) group. Then, 10 μL (10 nmol) of p65-siRNA was injected into the joint of the siRNA-p65 group. Meanwhile, 10 μL of negative siRNA was administered to the knee joint of the operated siRNA-neg group for comparison. The rats in the NC group did not receive surgery or drug intervention. After 4 weeks of right knee fixation in each group, X-ray measurements revealed significantly reduced degree of knee flexion contracture following p65-siRNA treatment (siRNA-neg: 77.73° ± 2.799°; siRNA-p65: 105.7° ± 2.629°, p < 0.0001). Histopathological examination revealed that the number of dense fibrous connective tissues decreased following p65-siRNA inhibition. Western blot analysis revealed significantly different expression levels of fibrosis-related proteins between the siRNA-p65 and siRNA-neg groups. Immunohistochemical analysis revealed a reduction in the average number of myofibroblasts in the siRNA-p65 group compared with that in the siRNA-neg group. Thus, intra-articular p65-siRNA injection could attenuate fibroblast activation and fibrosis-related protein production, suppress periarticular tissue fibrosis, and prevent joint contracture by downregulating the NF-κB p65 pathway. Statement of clinical significance: Intra-articular injection of p65-siRNA could reduce myofibroblast proliferation and fibrosis-related protein expression by downregulating the NF-κB p65 pathway, inhibit periarticular tissue fibrosis, and prevent joint adhesion, which represents a potential therapy in the prevention of joint fibrosis following traumatic injury.
Forensic Outpatient Systemic Therapy (in Dutch: Forensische Ambulante Systeem Therapie; FAST) is a promising treatment for juveniles showing severe antisocial behavior, including aggression, (domestic) violence, and delinquent behavior. FAST has a flexible intensity and length, addresses individual and systemic risk and protective factors, and is responsive to the abilities of the client (system), intervention characteristics all considered crucial for effective treatment. The current study will investigate whether FAST is effective in reducing aggression of the juvenile, in reaching client formulated subgoals, and in improving family functioning (i.e., reducing juvenile-caregiver conflict and increasing caregiver responsiveness). In addition, processes of change will be examined, as well as mediation by reaching client formulated subgoals and improved family functioning. A Multiple Case Experimental Design (MCED) with an ABC design will be performed (A = baseline, B = intervention, and C = follow-up). Juveniles with primary aggression and/or anger problems (N = 15) and their caregiver(s) will be recruited.
Objective. Glucocorticoids are important stress-responsive regulators of insulin-dependent metabolic processes realized through specific changes in genome function. The aim of this study was to investigate the impact of cortisol on insulin receptor and related genes expression in HEK293 cells upon induction the endoplasmic reticulum (ER) stress by tunicamycin and hypoxia. Methods. The human embryonic kidney cell line HEK293 was used. Cells were exposed to cortisol (10 µM) as well as inducers of hypoxia (dimethyloxalylglycine, DMOG; 0.5 mM) and ER stress (tunicamycin; 0.2 µg/ml) for 4 h. The RNA from these cells was extracted and reverse transcribed. The expression level of INSR, IRS2, and INSIG2 and some ER stress responsive genes encoding XBP1n, non-spliced variant, XBP1s, alternatively spliced variant of XBP1, and DNAJB9 proteins, was measured by quantitative polymerase chain reaction and normalized to ACTB. Results. We showed that exposure of HEK293 cells to cortisol elicited up-regulation in the expression of INSR and DNAJB9 genes and down-regulation of XBP1s, XBP1n, IRS2, and INSIG2 mRNA levels. At the same time, induction of hypoxia by DMOG led to an up-regulation of the expression level of most studied mRNAs: XBP1s and XBP1n, IRS2 and INSIG2, but did not change significantly INSR and DNAJB9 gene expression. We also showed that combined impact of cortisol and hypoxia introduced the up-regulation of INSR and suppressed XBP1n mRNA expression levels. Furthermore, the exposure of HEK293 cells to tunicamycin affected the expression of IRS2 gene and increased the level of XBP1n mRNA. At the same time, the combined treatment of these cells with cortisol and inductor of ER stress had much stronger impact on the expression of all the tested genes: strongly increased the mRNA level of ER stress dependent factors XBP1s and DNAJB9 as well as INSR and INSIG2, but down-regulated IRS2 and XBP1n. Conclusion. Taken together, the present study indicates that cortisol may interact with ER stress and hypoxia in the regulation of ER stress dependent XBP1 and DNAJB9 mRNA expression as well as INSR and its signaling and that this corticosteroid hormone modified the impact of hypoxia and especially tunicamycin on the expression of most studied genes in HEK293 cells. These data demonstrate molecular mechanisms of glucocorticoids interaction with ER stress and insulin signaling at the cellular level.
The dysfunction of reinforcement learning is emerging as a transdiagnostic dimension of mood and anxiety. Computational models of reinforcement learning may expedite our ability to identify predictors of response, thereby improving efficacy rates. We will will, first, examine the neural substrates of reinforcement learning in depression and anxiety, and, second, test a computational model of reinforcement learning as a predictor of response to an adapted version of behavioral activation psychotherapy. Subjects (N=10) will be enrolled in a two week evaluation, followed with a nine week weekly intervention program. Assessments will be conducted at baseline, and during the intervention as the 3-, 6-, 9-week follow-ups. Reinforcement learning will be measured using 3T magnetic resonance imaging during a computer task. All other measures include structured clinical interviews, questionnaires, and computer tasks.
BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
FIELD: medicine, phytotherapy, pharmacy. SUBSTANCE: invention relates to humans treatment against rheumatic diseases using phytopreparations. Tincture has aloe in combination with elecampane roots, swampy marsh cinquefoil roots and birch buds as plants of other species. Alcoholic extracts of these plants shows synergistic effect. EFFECT: enhanced curative effect, expanded spectrum of treatable rheumatic diseases, permanent effect. 2 cl, 1 tbl, 2 ex
Participants with R/R FL will receive 6 months of induction treatment with polatuzumab vedotin and lenalidomide at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and lenalidomide when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 24-month maintenance regimen consisting of lenalidomide and obinutuzumab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).